Matching articles for "fresh frozen plasma"
Which Oral Anticoagulant for Atrial Fibrillation?
The Medical Letter on Drugs and Therapeutics • April 11, 2016; (Issue 1492)
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral...
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral anticoagulants.
Kcentra: A 4-Factor Prothrombin Complex Concentrate for Reversal of Warfarin Anticoagulation
The Medical Letter on Drugs and Therapeutics • July 8, 2013; (Issue 1420)
The FDA has approved use of Kcentra (CSL Behring), a
human-derived 4-factor prothrombin complex concentrate
(PCC), for urgent reversal of warfarin anticoagulation
in adults with acute major bleeding. It is...
The FDA has approved use of Kcentra (CSL Behring), a
human-derived 4-factor prothrombin complex concentrate
(PCC), for urgent reversal of warfarin anticoagulation
in adults with acute major bleeding. It is the only
4-factor PCC available in the US.
Prothrombin Complex Concentrates to Reverse Warfarin-Related Bleeding
The Medical Letter on Drugs and Therapeutics • October 3, 2011; (Issue 1374)
Warfarin-related bleeding, especially intracranial hemorrhage,
can be catastrophic. Several products are available
to reverse warfarin’s anticoagulant...
Warfarin-related bleeding, especially intracranial hemorrhage,
can be catastrophic. Several products are available
to reverse warfarin’s anticoagulant effect.
Three New Drugs for Hereditary Angioedema
The Medical Letter on Drugs and Therapeutics • August 23, 2010; (Issue 1345)
In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary
angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and...
In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary
angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.